Background-Robot-assisted laparoscopic radical prostatectomy (RALP) has become increasingly common; however, there have been no nationwide, population-based, non-claimsbased studies to evaluate differences in outcomes between RALP and open radical retropubic prostatectomy (RRP).
Introduction
Robotic surgery systems have disseminated rapidly throughout the United States. For prostate cancer (PCa) treatment, the proportion of prostatectomies performed robotically has risen from 8% in 2003 to 67% in 2009 [1] . This increase has taken place despite a paucity of high-quality data supporting the benefits of robot-assisted laparoscopic radical prostatectomy (RALP) over open retropubic radical prostatectomy (RRP) [2] [3] [4] . Evaluation of clinical data on perioperative outcomes of RALP and RRP are generally limited to singleinstitution case series in which RALP was associated with lower estimated blood loss (EBL), shorter lengths of hospital stay (LOS), lower or similar rates of positive surgical margins (PSMs), and no difference in biochemical recurrence-free survival (bRFS) [2, 5, 6] . The only population-based studies are restricted to claims-based data [7] [8] [9] , with concerns about incomplete reporting and accuracy of data. Two of these studies were unable to differentiate between minimally invasive prostatectomy with or without the use of the robotic assistance [7, 8] . In addition, studies evaluating health-related quality-of-life outcomes (HRQOL) of urinary incontinence and impotence using a validated patientreported questionnaire among patients who had undergone RALP and those who had undergone RRP are even more sparse, with no multicenter or population studies available [2] [3] [4] [5] . A randomized controlled study of RALP versus RRP is currently enrolling patients [10] , but results will not be available for several years.
We therefore sought to evaluate surgical, oncologic, and HRQOL outcomes following RALP and RRP over a 10-yr interval in a nationwide, population-based cohort of US men with PCa.
Patients and methods

Study population
The men in this study are participants in the Health Professionals Follow-up Study (HPFS), a prospective study of 51 529 US male health professionals who enrolled in 1986 by completing a mailed questionnaire as previously described [11] . Participants complete biennial follow-up questionnaires to update information on new medical diagnoses and lifestyle (response rate: 96%).
After participants report a PCa diagnosis, we obtain medical records to confirm the diagnosis and record clinical information (eg, T stage, Gleason score), treatments, prostatespecific antigen (PSA) values at diagnosis, PSA levels after treatment (to identify events of biochemical recurrence), and metastasis. Participants also complete biennial follow-up questionnaires to update data on treatments, PSA levels, and clinical progression. The base population for this analysis included men who were diagnosed with PCa after January 1, 2000, and were treated with radical prostatectomy (RP) as primary therapy within 1 yr of diagnosis between 2000 and 2010. The main analysis included the 903 men treated with RALP and RRP, excluding those who had prostatectomy with a pure laparoscopic (n = 32), perineal approach (n = 28), or had unknown type (n = 102).
Surgical technique and perioperative and oncologic outcomes
The medical records of patients who underwent RALP or RRP were evaluated to determine perioperative outcomes. BRFS was defined as PSA level >0.2 ng/ml after surgery and for at least two consecutive measures (date of failure was the date of first increase) [12, 13] . Men for whom we could not ascertain a PSA recurrence but who reported metastasis or died of PCa were assigned a date of recurrence as the earliest date for any of these events. We used modified D'Amico criteria as previously described (that do not distinguish between T2 substages) because the substage definitions were changed twice by the American Joint Commission on Cancer during the study period [14] .
Patient-reported outcomes
We used the Expanded Prostate Cancer Index Composite 26 (EPIC-26) to assess HRQOL in the HPFS on the 2010 prostate biennial questionnaire [15, 16] . Men who returned their baseline questionnaire before January 1, 2009, were eligible for this mailing, which included 650 of the 903 men who underwent RALP or RPP. The 2010 questionnaire was completed by 614 of 650 men (response rate: 94.5%). For the patient-reported outcomes analysis, we restricted the population to 600 men who completed the questionnaire ≥2 yr after prostatectomy.
We measured cancer care satisfaction using the Satisfaction Scale for Cancer Care (SCA), developed and validated by our group and previously described [15, 17] . Unlike other instruments focused on satisfaction with cancer care processes, the SCA instrument is unique in providing a robust, valid measure of satisfaction with care outcome (Cronbach α = 0.88) [18] . Satisfaction data were collected on the 2010 prostate biennial questionnaire.
Statistical analysis
We compared patient and tumor characteristics, perioperative outcomes, and oncologic outcomes between RALP and RRP groups. The t test and Wilcoxon test were used to compare means and medians across groups and the Fisher exact test was used for categorical variables (p < 0.05 was considered significant). For variables that had a possible secular trend over time (ie, PSA value, biopsy Gleason score, risk score, pathologic Gleason score, and LOS), logistic or linear regression models were used to test whether there were differences by type of prostatectomy, adjusting for calendar year of surgery (continuous, years).
Recurrence was defined as any report of biochemical recurrence, metastasis, or PCa death, using the earliest date available as the recurrence date. We used a Kaplan-Meier plot to illustrate recurrence-free survival (RFS) and calculated risk of recurrence within 3 yr and 5 yr using logistic regression models adjusted for age at diagnosis, clinical stage, biopsy Gleason score, PSA at diagnosis, and calendar year of surgery.
We used linear regression models to test whether there were differences in HRQOL domains and satisfaction with cancer care outcome by type of prostatectomy, adjusting for age at diagnosis (continuous, years), PSA value at diagnosis (continuous, ng/ml), calendar year of surgery (continuous, years), and time since RP (continuous, months). All analyses were performed using SAS v.9.1 (SAS Institute Inc., Cary, NC, USA) and results with a twosided p value <0.05 were considered statistically significant.
Results
Patient and tumor characteristics and use of robot-assisted laparoscopic radical prostatectomy
Between 2000 and 2010, 1065 men were diagnosed with PCa, of whom 282 underwent RALP and 621 underwent RRP; those in the RALP and RRP groups are the subject of this study (N = 903). Patients in the RALP group were less likely to have T2 or higher clinical stage than RRP (20.6% vs 33.0%; p = 0.0002). When corrected for year of surgery, there was no significant difference in PSA value at diagnosis (p = 0.09), biopsy Gleason score (p = 0.71), or D'Amico risk score (0.10) ( Table 1 ). Use of RALP grew steadily over the study period, composing only 4.5% of procedures in 2003, 28.6% in 2005, 63.9% in 2007, and 85.2% in 2009 ( Fig. 1 ). Use of RP as primary treatment in the larger cohort of men with PCa diminished slightly over time, with 40.9% of men receiving RP in 2003 and 36.5% in 2009.
Perioperative outcomes
Lymph node dissection status, LOS, EBL, and transfusion status differed significantly between the treatment groups ( Table 2) , and these results remained significant after adjustment for calendar year of surgery. Lymph node dissection was more common in higher-risk patients than low-or intermediate-risk patients in both surgical groups (p < 0.01 for both (data not shown). However, among the low-risk patients, a higher proportion of RRP patients (77.1%) had a lymph node dissection compared to RALP patients (35.3%), as well as among intermediate-risk patients (94.8% vs 64.8%, respectively) (p < 0.0001) (data not shown). There was no difference in the proportion of nerve-sparing between RALP and RRP overall and by clinical stage (data not shown), with the majority of patients getting bilateral nerve sparing (70.7% vs 68.3%, respectively; p = 0.39), and no difference in seminal vesicle removal (95.2% vs 96.7%, respectively; p = 0.34) ( Table 2 ).
Patients in the RALP group compared to RRP were 82% less likely to receive a lymph node dissection (95% confidence interval [CI], 0.11-0.27; p < 0.0001). After adjusting for calendar year of surgery, RALP patients had, on average, 495 ml less EBL (95% CI, 389-601; p < 0.0001), were 83% less likely to receive a blood transfusion (95% CI, 0.07-0.41; p < 0.0001), and experienced, on average, a 0.5-d shorter hospital stay (95% CI, 0.14-0.84; p = 0.007) (data not shown). Between 2004-2010 (when ample cases were available in both groups for comparison per year of surgery), the RRP group experienced a decrease in average successive LOS (0.18 d/yr, p = 0.001) and EBL (66 ml/yr, p = 0.01), whereas the RALP group did not (LOS: 0.11 d/yr, p = 0.10; EBL: 1.5 ml/yr, p = 0.85).
Oncologic outcomes
Overall, pathologic T stage did not differ significantly among patients who had undergone RALP and those who had undergone RRP, nor did presence of T3 or higher disease (22.2% vs 20.7%, respectively; p = 0.66), nodal metastasis (p = 0.74), Gleason score (p = 0.75, adjusted for year of surgery), or positive surgical margins (24.5% vs 23.1%, respectively; p = 0.51) ( Table 3 ). After correcting for clinical stage, pathologic stage and PSMs remained not significantly different between the groups (data not shown).
Median follow-up was 2.4 yr in the RALP group and 6.8 yr in the RRP group. There were 24 recurrence events in the RALP group (all of which were biochemical) and 116 recurrence events in the RRP group (110 of which were biochemical, 4 were metastasis, and 2 were PCa death). Kaplan-Meier analysis demonstrated no difference in RFS (p = 0.23) ( Fig. 2 
Health-related quality-of-life outcomes
The EPIC-26 questionnaire, which was included as part of the 2010 prostate follow-up questionnaire, was sent to 147 patients in the RALP group and 503 patients in the RRP group, with a response rate of 95.2% (140 of 147 patients) and 94.2% (474 of 503 patients), respectively. The analysis was limited to 600 men-132 patients in the RALP group and the 468 patients in the RRP group-who completed the questionnaire ≥2 yr after prostatectomy. There was no significant difference in HRQOL outcomes among the groups overall or in regard to any of the specific domains or when stratified by low-and intermediate-or highrisk groups (Table 4 ).
Discussion
Despite the lack of population-based data (apart from claims data) comparing RALP to RRP, there has been rapid propagation of robotic platforms across the United States, with the majority of RPs now being performed with robotic assistance [1, 19, 20] . Most data come from select high-volume, single-institution series and may not be generalizable to the population has a whole [2] [3] [4] [5] . Three population-based studies using claims-based data are limited by concerns of incomplete coding of diagnosis by urologists [7] [8] [9] . Our study provides data from a nationwide cohort of patients with centralized reporting of clinical data.
We found somewhat higher use of RALP (4.5% in 2003 to 85.2% in 2009) in comparison to a survey of urologists' case logs reporting an increase in proportion of RALP for prostatectomy from 8% in 2003 to 67% in 2009 [1] . In addition, two studies using Medicare data found the proportion of minimally invasive prostatectomies increased from 4.9% to 9.2% in 2003 to 43.2% in 2006 and 44.5% in 2007 [7, 19] . This difference may be due to our cohort being health professionals with better access to care and knowledge about new technologies with the potential for improved outcomes.
Previously reported advantages of RALP over RRP by single-institution studies were supported by our study. EBL in single-institution studies ranged from 100 ml to 300 ml for RALP and 450 ml to 800 ml for RRP; we found median values of 150 ml and 700 ml, respectively [21] [22] [23] . The 4.5-fold higher rate of blood transfusions in RRP than RALP noted in a meta-analysis [5] was supported by our findings of a 7.0-fold higher proportion of transfusions in RRP. This may be due to improvements in RALP technique over time. LOSs are consistently lower with RALP, as seen in the population-based studies using data from the Surveillance Epidemiology and End Results study and Medicare data [4, 7, 24, 25] with median LOS of 2 d for RALP and 3 d for RRP, similar to our findings of 1 d and 3 d, respectively.
Oncologic outcomes are of paramount importance when comparing these two techniques. Surgical margins are associated with future biochemical recurrence; since no follow-up is required, many studies use surgical margins as a surrogate for oncologic efficacy. Some single-institution studies reported a lower rate of positive margins with RALP compared to RRP, ranging from 15% to 22% and from 33% to 36% [26] [27] [28] , whereas others found no difference, with respective rates of 16% to 34% and 17% to 30% [5, 24, 25, 29] similar to our findings. More important than surgical margins for evaluation of oncologic outcomes is bRFS, as this is more closely associated with mortality and dictates further cancer therapies. Only one study reported on recurrence [30] and found no difference in biochemical recurrence among men who had undergone RALP and those who had undergone RRP (16% vs 16.5%; p = 0.19), with median follow-ups of 8 mo and 17 mo, respectively. We observed no difference in RFS between groups. Because follow-up was longer in the RRP than RALP group, we performed a logistic regression analysis restricted to patients with at least 3 yr and 5 yr of follow-up, and this also showed no significant differences. Since median time to recurrence in the longer follow-up RRP group was 2.5 yr, the restriction of the subsequent recurrence-free logistic analysis to 3 yr and 5 yr would appropriately capture most events. In addition, similar to another population-based study [31] , we found that patients undergoing RALP were less likely to have a lymph node dissection than the RRP group.
Another suggested benefit of RALP from early single-institution studies [32] was the potential for improved urinary incontinence and sexual function [5, 32] . However, many of these studies did not use validated questionnaires and were from single institutions, potentially limiting generalizability [2] . One single-institution study using a validated questionnaire also found no difference in HRQOL [33] , as we did.
Outcomes following RP, including perioperative, oncologic, and HRQOL, are multifactorial. Pretreatment patient/tumor characteristics and baseline function play major roles, as well as surgeon experience and technique. Therefore, firm conclusions cannot be drawn from any single-surgeon series. The strength of our population-based study is that all states within the United States were represented, allowing for a diverse cohort of patients treated by surgeons with varying experience and techniques. Our study does not attempt to determine whether RALP or RRP outcomes are better between the best or worst surgeon, but rather to describe outcomes within the United States.
Individual surgeons can compare their specific outcomes to national averages to determine areas where further improvements can be made.
Our study needs to be interpreted with respect to its limitations. First, although this is a nationwide cohort, it is limited to health professionals who may have different access and knowledge regarding health-care options and providers, thus influencing rates of RALP and RRP. Second, this is an observational study and factors that influenced patients to select RRP or RALP also could influence the observed outcomes; a randomized trial would be required to avoid this potential confounding. Third, our median follow-up time is limited to 2.4 yr in the RALP patients and 6.8 yr in the RRP patients. We accounted for this difference by reporting results from the Kaplan-Meier analysis and by restricting the analysis to patients with at least 3 yr or 5 yr of follow-up. Last, it is important to note that although the RRP technique was introduced more than three decades ago and has matured over time, the RALP technique was only introduced within the last decade and, therefore, continued to evolve and mature over the study period. Additional follow-up is needed to better evaluate oncologic outcomes of recurrence as well as mortality between the groups.
Conclusions
In this nationwide, population-based cohort study, we found that men who undergo RALP are more likely to have been diagnosed with lower clinical stage cancer and also have improved perioperative parameters including less EBL, fewer transfusions, and shorter LOS while maintaining similar HRQOL outcomes. Further follow-up is needed to evaluate more fully the oncologic outcomes of biochemical recurrence and mortality. Table 2 Comparison of perioperative outcomes among men who underwent radical prostatectomy by robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy Table 3 Comparison of oncologic outcomes among men who underwent radical prostatectomy by robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy 0.62 HRQOL = health-related quality of life; RALP = robot-assisted laparoscopic radical prostatectomy; RRP = radical retropubic prostatectomy.
*
Up to 5 men who had RALP and up to 24 men who had RRP were missing one of the HRQOL domains from the questionnaire. ** Resulting domain scores for the Expanded Prostate Cancer Index Composite 26 (urinary incontinence, urinary obstruction, sexual, bowel hormonal/vitality) is on a 0-100 scale, with higher values representing a more favorable HRQOL. Resulting scores for the Satisfaction Scale for Cancer Care (outcome satisfaction) is on a 0-100 scale, with higher values representing more satisfaction. † P values represent significance of the surgical technique variable (RALP vs RRP) in multivariable linear models, with HRQOL score as the dependent variable, adjusted for patient age at diagnosis, D'Amico risk group, and time since prostatectomy. The models by risk group were not adjusted for risk group.
